PICKERING, ON, March 12, 2019 /CNW/ - Purdue Pharma (Canada) announced today that Health Canada has issued a Notice of Compliance (NOC) for an expanded indication for FOQUEST® (methylphenidate HCl controlled-release capsules), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents six years of age and older.1 This announcement follows the December 6, 2017 Notice of Compliance for FOQUEST for the treatment of ADHD in adults 18 years of age and older.2
